Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365971 | 1.00 | NOTUM (0.44) | NOTUMACP1S1PR1S1PR3RXRA | |
| Carbamic Acid SCHEMBL11786912 | 0.86 | NOTUM (0.47) | NOTUMACP1RXRARXRBRXRG | |
| Tetrahydrofuran SCHEMBL8652793 | 0.84 | NOTUM (0.36) | NOTUMACP1S1PR1S1PR3TAS2R14 | |
| SCHEMBL131138 | 0.84 | NOTUM (0.50) | NOTUMACP1S1PR1S1PR3TAS2R14 | |
| SCHEMBL1082212 | 0.84 | NOTUM (0.50) | NOTUMACP1S1PR1S1PR3TAS2R14 | |
| SCHEMBL1445873 | 0.81 | NOTUM (0.48) | NOTUMACP1S1PR1S1PR3TAS2R14 | |
| SCHEMBL31749284 | 0.81 | NOTUM (0.34) | NOTUMCA1CA2CA5ACA9 | |
| SCHEMBL5779081 | 0.81 | NOTUM (0.34) | NOTUMCA1CA2CA5ACA9 | |
| SCHEMBL9693899 | 0.81 | CES2 (0.42) | RXRARXRBRXRGHDAC3HDAC1 | |
| SCHEMBL4461544 | 0.81 | CES2 (0.48) | RXRARXRBRXRGHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 509 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957312-A | Aryl silicon compound of conjugated olefin and preparation method and application thereof | 南京工业大学 | 2022-08-30 | — | — | CN | claimed |
| EP-3543319-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2019-09-25 | — | — | EP | claimed |
| US-20140120626-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2014-05-01 | — | — | US | claimed |
| EP-2707465-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2014-03-19 | — | — | EP | claimed |
| CN-102174019-B | Method for synthesizing organic compounds | NOVARTIS AG | 2013-02-13 | — | — | CN | claimed |
| WO-2012153132-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2012-11-15 | — | — | WO | claimed |
| EP-1896426-B1 | PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-11 | — | — | EP | claimed |
| CN-102174019-A | method for synthesizing organic compounds | NOVARTIS AG | 2011-09-07 | — | — | CN | claimed |
| US-20100280257-A1 | PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS | ABEL STEPHAN | 2010-11-04 | — | — | US | claimed |
| US-20080200692-A1 | Process For the Synthesis of Organic Compounds | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | claimed |
| CN-101189212-A | Method for synthesizing organic compounds | NOVARTIS AG (CH) | 2008-05-28 | — | — | CN | claimed |
| EP-1896426-A2 | PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-03-12 | — | — | EP | claimed |
| WO-2006135640-A2 | PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-21 | — | — | WO | claimed |
| US-12552801-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2025264844-A1 | HETEROCYCLIC GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025264837-A1 | NAPHTHYRIDINE GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-5098930-A | Inhibitors of lipoxygenase for treatment of diseases mediated with leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-03-24 | — | — | US | disclosed |
| EP-0409413-A2 | Diaryl ether heterocycles | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-01-23 | — | — | EP | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0375404-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200692-A1 | Process For the Synthesis of Organic Compounds | ODC1, AZI2, NISCH | NOTUM 2412/4885ACP1 3217/4885S1PR1 4380/4885 |
| US-20100280257-A1 | PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS | ODC1, AZI2, NISCH | NOTUM 2412/4885ACP1 3217/4885S1PR1 4380/4885 |
| US-12552801-B2 | Indazole derivatives | EGFR, ABL1, ERBB3 | NOTUM 2985/4885ACP1 1473/4885S1PR1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.